MedTrace Logo

A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants

NCT06625671 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2025-12-18

No results posted yet for this study

Summary

A Phase 1/2a Study of DB-2304 in Healthy Participants and Participants with Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus

Conditions

  • Systemic Lupus Erythematosus (SLE)

Interventions

DRUG

Prednisone

Prednisone

DRUG

DB-2304

DB-2304

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • DualityBio Inc.

    lead INDUSTRY

Principal Investigators

  • Lily Hu · DualityBio Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-04
Primary Completion
2026-03-23
Completion
2026-06-05
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06625671 on ClinicalTrials.gov